Analyst Conference Summaries
May 4, 2017
Bioverativ (BIVV) is a commercial-stage biotechnology company specializing in hemophilia therapies and developing therapies for other blood disorders. It was spun off from Biogen (BIIB).
More Analyst Conference Pages:
Disclaimer: My analyst summaries may include both condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. These are my personal notes which I share with other investors and which I use as the basis of my blog and Seeking Alpha articles.
Copyright 2017 William P. Meyers